强心苷 (CG) 传统上用于治疗心脏病，现在也显示出治疗癌症的前景。然而，该领域的临床研究缺乏全面的综述，迄今为止，CG尚未广泛融入临床癌症治疗。这篇综述涵盖了过去五年的临床研究，强调了 CG 在降低癌症风险、提高化疗效果、减轻化疗引起的副作用和改善生活质量方面的潜力。未来的临床试验应该个性化 CG 的剂量，整合分子测试并研究免疫原性细胞死亡诱导以及 CG 治疗骨癌和转移的潜力。优化 CG 的再利用以进行抗癌治疗需要考虑特定的 CG、癌症类型和并发药物。版权所有 © 2024 Elsevier Ltd。保留所有权利。

Cardiac glycosides (CGs), which are traditionally used for heart disease, show promise for cancer therapy. However, there is a lack of a comprehensive review of clinical studies in this area, and so far, CGs have not been widely integrated into clinical cancer treatment. This review covers clinical studies from the past five years, highlighting the potential of CGs to reduce cancer risk, enhance chemotherapy effectiveness, mitigate chemotherapy-induced side effects and improve quality of life. Future clinical trials should personalize the dosage of CGs, integrate molecular testing and investigate immunogenic cell death induction and the potential of CGs for treating bone cancer and metastasis. Optimizing the repurposing of CGs for anticancer treatment requires consideration of specific CGs, cancer types and concurrent medications.Copyright © 2024 Elsevier Ltd. All rights reserved.